EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited

View source ↗

Summary

The EMA authorised Gobivaz (golimumab) for multiple inflammatory diseases. Indications include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic ar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Juvenile Idiopathic Arthritis
• Non-radiographic Axial Spondyloarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Gobivaz (golimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile;Arthritis, Psoriatic;Axial Spondyloarthritis;Colitis, Ulcerative;Non-Radiographic Axial Spondyloarthritis. MAH: Advanz Pharma Limited. Decision date: 17/11/2025